Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 9/20 | 0.44 |
| ▸ | NPC1 | O15118 | 7/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL162111 | 0.90 | RAB9A (0.46) | RAB9ANPC1KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL163354 | 0.90 | SMN1; SMN2 (0.45) | RAB9ANPC1KMT2ASMN1; SMN2MEN1 | |
| Hydrochloric Acid SCHEMBL161862 | 0.90 | KDM4E (0.44) | SMN1; SMN2CNR2ALDH1A1 | |
| SCHEMBL159074 | 0.89 | DGAT1 (0.42) | SMN1; SMN2DGAT1EPHX2 | |
| SCHEMBL161913 | 0.87 | NAMPT (0.47) | RAB9ANPC1SMN1; SMN2ALDH1A1HSD17B10 | |
| SCHEMBL163373 | 0.83 | MEN1 (0.50) | KMT2AMEN1 | |
| SCHEMBL161041 | 0.82 | ATM (0.41) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL162878 | 0.82 | EPHX1 (0.49) | RAB9ANPC1SMN1; SMN2ALDH1A1DGAT1 | |
| SCHEMBL162592 | 0.81 | BLM (0.47) | RAB9ANPC1KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL158330 | 0.80 | RAB9A (0.51) | RAB9AKMT2ASMN1; SMN2MEN1DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2611783-A2 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | Piramal Enterprises Limited (IN) | 2013-07-10 | — | — | EP | claimed |
| US-20130158075-A1 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | Piramal Enterprises Limited (IN) | 2013-06-20 | — | — | US | claimed |
| WO-2012029032-A2 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2012-03-08 | — | — | WO | claimed |
| CN-103228633-A | Heterocyclic compounds as DGAT1 inhibitors | PIRAMAL LIFE SCIENCES LTD | 2013-07-31 | — | — | CN | disclosed |
| EP-2611783-A2 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | Piramal Enterprises Limited (IN) | 2013-07-10 | — | — | EP | disclosed |
| US-20130158075-A1 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | Piramal Enterprises Limited (IN) | 2013-06-20 | — | — | US | disclosed |
| WO-2012029032-A2 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158075-A1 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | DGAT1, DGAT2, SOAT1 | RAB9A 1781/4885NPC1 86/4885KMT2A 2187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.